Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 202

1.

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease.

Farlow MR, Andreasen N, Riviere ME, Vostiar I, Vitaliti A, Sovago J, Caputo A, Winblad B, Graf A.

Alzheimers Res Ther. 2015 Apr 27;7(1):23. doi: 10.1186/s13195-015-0108-3. eCollection 2015.

2.

Comprehensive gene- and pathway-based analysis of depressive symptoms in older adults.

Nho K, Ramanan VK, Horgusluoglu E, Kim S, Inlow MH, Risacher SL, McDonald BC, Farlow MR, Foroud TM, Gao S, Callahan CM, Hendrie HC, Niculescu AB, Saykin AJ.

J Alzheimers Dis. 2015 Jan 1;45(4):1197-206. doi: 10.3233/JAD-148009.

PMID:
25690665
3.

Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease.

Farlow MR, Sadowsky CH, Velting DM, Meng X, Islam MZ.

CNS Neurosci Ther. 2015 Jun;21(6):513-9. doi: 10.1111/cns.12385. Epub 2015 Feb 10.

PMID:
25675992
4.

Cerebral hypometabolism and grey matter density in MAPT intron 10 +3 mutation carriers.

Deters KD, Risacher SL, Farlow MR, Unverzagt FW, Kareken DA, Hutchins GD, Yoder KK, Murrell JR, Spina S, Epperson F, Gao S, Saykin AJ, Ghetti B.

Am J Neurodegener Dis. 2014 Dec 5;3(3):103-14. eCollection 2014.

5.

Factors associated with the onset and persistence of post-lumbar puncture headache.

Monserrate AE, Ryman DC, Ma S, Xiong C, Noble JM, Ringman JM, Morris JC, Danek A, Müller-Sarnowski F, Clifford DB, McDade EM, Brooks WS, Darby DG, Masters CL, Weston PS, Farlow MR, Graff-Radford NR, Salloway SP, Fagan AM, Oliver A, Bateman RJ; Dominantly Inherited Alzheimer Network.

JAMA Neurol. 2015 Mar;72(3):325-32. doi: 10.1001/jamaneurol.2014.3974.

PMID:
25622095
6.

Protective variant for hippocampal atrophy identified by whole exome sequencing.

Nho K, Kim S, Risacher SL, Shen L, Corneveaux JJ, Swaminathan S, Lin H, Ramanan VK, Liu Y, Foroud TM, Inlow MH, Siniard AL, Reiman RA, Aisen PS, Petersen RC, Green RC, Jack CR Jr, Weiner MW, Baldwin CT, Lunetta KL, Farrer LA; MIRAGE (Multi-Institutional Research on Alzheimer Genetic Epidemiology) Study, Furney SJ, Lovestone S, Simmons A, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H; AddNeuroMed Consortium, McDonald BC, Farlow MR, Ghetti B; Indiana Memory and Aging Study, Huentelman MJ, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative.

Ann Neurol. 2015 Mar;77(3):547-52. doi: 10.1002/ana.24349. Epub 2015 Feb 14.

PMID:
25559091
7.

Rarity of the Alzheimer disease-protective APP A673T variant in the United States.

Wang LS, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, Murcia JD, Cannon-Albright L, Baldwin CT, Zetterberg H, Blennow K, Kukull WA, Faber KM, Schupf N, Norton MC, Tschanz JT, Munger RG, Corcoran CD, Rogaeva E; Alzheimer's Disease Genetics Consortium, Lin CF, Dombroski BA, Cantwell LB, Partch A, Valladares O, Hakonarson H, St George-Hyslop P, Green RC, Goate AM, Foroud TM, Carney RM, Larson EB, Behrens TW, Kauwe JS, Haines JL, Farrer LA, Pericak-Vance MA, Mayeux R, Schellenberg GD; National Institute on Aging-Late-Onset Alzheimer’s Disease (NIA-LOAD) Family Study, Albert MS, Albin RL, Apostolova LG, Arnold SE, Barber R, Barmada M, Barnes LL, Beach TG, Becker JT, Beecham GW, Beekly D, Bennett DA, Bigio EH, Bird TD, Blacker D, Boeve BF, Bowen JD, Boxer A, Burke JR, Buxbaum JD, Cairns NJ, Cao C, Carlson CS, Carroll SL, Chui HC, Clark DG, Cribbs DH, Crocco EA, DeCarli C, DeKosky ST, Demirci FY, Dick M, Dickson DW, Duara R, Ertekin-Taner N, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Glass JD, Graff-Radford NR, Growdon JH, Hamilton RL, Hamilton-Nelson KL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jarvik GP, Jicha GA, Jin LW, Jun G, Jun G, Kamboh MI, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Kramer JH, LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieberman AP, Lopez OL, Lunetta KL, Lyketsos CG, Mack WJ, Marson DC, Martin ER, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam WM, Miller BL, Miller CA, Miller JW, Montine TJ, Morris JC, Murrell JR, Olichney JM, Parisi JE, Perry W, Peskind E, Petersen RC, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raskind M, Reiman EM, Reisberg B, Reitz C, Ringman JM, Roberson ED, Rosen HJ, Rosenberg RN, Sano M, Saykin AJ, Schneider JA, Schneider LS, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Tanzi RE, Thornton-Wells TA, Trojanowski JQ, Troncoso JC, Tsuang DW, Van Deerlin VM, Van Eldik LJ, Vardarajan BN, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Wishnek S, Woltjer RL, Wright CB, Younkin SG, Yu CE, Yu L.

JAMA Neurol. 2015 Feb;72(2):209-16. doi: 10.1001/jamaneurol.2014.2157.

PMID:
25531812
8.

Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor.

Grossberg GT, Farlow MR, Meng X, Velting DM.

Curr Alzheimer Res. 2015;12(1):53-60.

PMID:
25523430
9.

A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease.

Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Velting DM.

Alzheimer Dis Assoc Disord. 2015 Apr-Jun;29(2):110-6. doi: 10.1097/WAD.0000000000000073.

PMID:
25437301
10.

FASTKD2 is associated with memory and hippocampal structure in older adults.

Ramanan VK, Nho K, Shen L, Risacher SL, Kim S, McDonald BC, Farlow MR, Foroud TM, Gao S, Soininen H, Kłoszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Aisen PS, Petersen RC, Jack CR Jr, Shaw LM, Trojanowski JQ, Weiner MW, Green RC, Toga AW, De Jager PL, Yu L, Bennett DA, Saykin AJ.

Mol Psychiatry. 2014 Nov 11. doi: 10.1038/mp.2014.142. [Epub ahead of print]

PMID:
25385369
11.

Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study.

Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YS, Beecham GW, Rajbhandary RA, Hamilton-Nelson KL, Wang LS, Kauwe JS, Huentelman MJ, Myers AJ, Bird TD, Boeve BF, Baldwin CT, Jarvik GP, Crane PK, Rogaeva E, Barmada MM, Demirci FY, Cruchaga C, Kramer PL, Ertekin-Taner N, Hardy J, Graff-Radford NR, Green RC, Larson EB, St George-Hyslop PH, Buxbaum JD, Evans DA, Schneider JA, Lunetta KL, Kamboh MI, Saykin AJ, Reiman EM, De Jager PL, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Martin ER, Haines JL, Mayeux RP, Farrer LA, Schellenberg GD, Pericak-Vance MA; Alzheimer Disease Genetics Consortium, Albert MS, Albin RL, Apostolova LG, Arnold SE, Barber R, Barnes LL, Beach TG, Becker JT, Beekly D, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Cantwell LB, Cao C, Carlson CS, Carney RM, Carrasquillo MM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cribbs DH, Crocco EA, DeCarli C, DeKosky ST, Dick M, Dickson DW, Duara R, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Kramer JH, LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieberman AP, Lin CF, Lopez OL, Lyketsos CG, Mack WJ, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Murrell JR, Olichney JM, Pankratz VS, Parisi JE, Paulson HL, Peskind E, Petersen RC, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosen HJ, Rosenberg RN, Sano M, Schneider LS, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Tanzi RE, Thornton-Wells TA, Trojanowski JQ, Troncoso JC, Valladares O, Van Deerlin VM, Van Eldik LJ, Vardarajan BN, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Wishnek S, Woltjer RL, Wright CB, Younkin SG, Yu CE, Yu L.

JAMA Neurol. 2014 Nov;71(11):1394-404. doi: 10.1001/jamaneurol.2014.1491. Erratum in: JAMA Neurol. 2014 Nov;71(11):1457.

12.

The role of choroid plexus in IVIG-induced beta-amyloid clearance.

Gu H, Zhong Z, Jiang W, Du E, Dodel R, Liu J, Farlow MR, Zheng W, Du Y.

Neuroscience. 2014 Jun 13;270:168-76. doi: 10.1016/j.neuroscience.2014.04.011. Epub 2014 Apr 16.

PMID:
24747018
13.

Cognitive dysfunction and greater visit-to-visit systolic blood pressure variability.

Epstein NU, Lane KA, Farlow MR, Risacher SL, Saykin AJ, Gao S; Alzheimer's Disease Neuroimaging Initiative.

J Am Geriatr Soc. 2013 Dec;61(12):2168-73.

14.

Medication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging Initiative.

Epstein NU, Guo R, Farlow MR, Singh JP, Fisher M.

Drugs Aging. 2014 Feb;31(2):125-9. doi: 10.1007/s40266-013-0143-3.

PMID:
24357133
15.

Comparing clinical profiles in Alzheimer's disease and Parkinson's disease dementia.

Farlow MR, Schmitt F, Aarsland D, Grossberg GT, Somogyi M, Meng X.

Dement Geriatr Cogn Dis Extra. 2013 Sep 11;3(1):281-90. doi: 10.1159/000351861. eCollection 2013.

16.

Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects.

Millard SP, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang D, Yu CE, Peskind ER, Bekris LM.

Neurobiol Aging. 2014 Feb;35(2):357-64. doi: 10.1016/j.neurobiolaging.2013.07.027. Epub 2013 Sep 4.

17.

A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.

Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Somogyi M.

CNS Neurosci Ther. 2013 Oct;19(10):745-52. doi: 10.1111/cns.12158. Epub 2013 Aug 7.

18.

Immunotherapy for Alzheimer's disease.

Farlow MR, Brosch JR.

Neurol Clin. 2013 Aug;31(3):869-78. doi: 10.1016/j.ncl.2013.03.012. Epub 2013 May 18. Review.

PMID:
23896510
19.

Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel.

Kim S, Swaminathan S, Inlow M, Risacher SL, Nho K, Shen L, Foroud TM, Petersen RC, Aisen PS, Soares H, Toledo JB, Shaw LM, Trojanowski JQ, Weiner MW, McDonald BC, Farlow MR, Ghetti B, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

PLoS One. 2013 Jul 23;8(7):e70269. doi: 10.1371/journal.pone.0070269. Print 2013.

20.

Identification of functional variants from whole-exome sequencing, combined with neuroimaging genetics.

Nho K, Corneveaux JJ, Kim S, Lin H, Risacher SL, Shen L, Swaminathan S, Ramanan VK, Liu Y, Foroud T, Inlow MH, Siniard AL, Reiman RA, Aisen PS, Petersen RC, Green RC, Jack CR, Weiner MW, Baldwin CT, Lunetta K, Farrer LA; Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study, Furney SJ, Lovestone S, Simmons A, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H; AddNeuroMed Consortium, McDonald BC, Farlow MR, Ghetti B; Indiana Memory and Aging Study, Huentelman MJ, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative (ADNI).

Mol Psychiatry. 2013 Jul;18(7):739. doi: 10.1038/mp.2013.81. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk